| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3864739 | The Journal of Urology | 2013 | 5 Pages |
Abstract
Neoadjuvant cisplatin and gemcitabine yield appreciable pathological response rates in patients with muscle invasive bladder cancer. Since pathological response has been implicated as a potential surrogate for survival in muscle invasive bladder cancer, these data suggest that neoadjuvant cisplatin and gemcitabine may warrant further prospective assessment.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Bertram E. Yuh, Nora Ruel, Timothy G. Wilson, Nicholas Vogelzang, Sumanta K. Pal,